研究者詳細 - 野間　和広

Minimal invasive esophagectomy:current state of art of each approach 腹臥位胸腔鏡下食道切除における微細層構造を意識した安全な上縦隔郭清術

野間和広, 白川靖博, 鳴坂徹, 前田直見, 二宮卓之, 田辺俊介, 楳田祐三, 西崎正彦, 香川俊輔, 藤原俊義

日本内視鏡外科学会雑誌 22 ( 7 ) S2 - 4 2017年12月

高難度症例への挑戦(胸腔) 腹臥位胸腔鏡下食道癌手術における困難症例に対する挑戦

白川靖博, 鳴坂徹, 前田直見, 二宮卓之, 田辺俊輔, 野間和広, 楳田祐三, 西崎正彦, 香川俊輔, 藤原俊義

日本内視鏡外科学会雑誌 22 ( 7 ) VW2 - 1 2017年12月

Iron depletion is a novel therapeutic strategy to target cancer stem cells. 国際誌

Takayuki Ninomiya, Toshiaki Ohara, Kazuhiro Noma, Yuki Katsura, Ryoichi Katsube, Hajime Kashima, Takuya Kato, Yasuko Tomono, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Fumiaki Kimura, Ling Chen, Tomonari Kasai, Masaharu Seno, Akihiro Matsukawa, Toshiyoshi Fujiwara

Oncotarget 8 ( 58 ) 98405 - 98416 2017年11月

記述言語：英語出版者・発行元：IMPACT JOURNALS LLC

Adequate iron levels are essential for human health. However, iron overload can act as catalyst for the formation of free radicals, which may cause cancer. Cancer stem cells (CSCs), which maintain the hallmark stem cell characteristics of self-renewal and differentiation capacity, have been proposed as a driving force of tumorigenesis and metastases. In the present study, we investigated the role of iron in the proliferation and stemness of CSCs, using the miPS-LLCcm cell model. Although the anti-cancer agents fluorouracil and cisplatin suppressed the proliferation of miPS-LLCcm cells, these drugs did not alter the expression of stemness markers, including Nanog, SOX2, c-Myc, Oct3/4 and Klf4. In contrast, iron depletion by the iron chelators deferasirox and deferoxamine suppressed the proliferation of miPS-LLCcm cells and the expression of stemness markers. In an allograft model, deferasirox inhibited the growth of miPS-LLCcm implants, which was associated with decreased expression of Nanog and Sox2. Altogether, iron appears to be crucial for the proliferation and maintenance of stemness of CSCs, and iron depletion may be a novel therapeutic strategy to target CSCs.

DOI： 10.18632/oncotarget.21846

合併症ゼロを目指した手術(食道) 食道癌手術における術後合併症ゼロを目指したわれわれの工夫

白川靖博, 鳴坂徹, 前田直見, 二宮卓之, 田辺俊介, 楳田祐三, 西崎正彦, 香川俊輔, 櫻間教文, 野間和広, 藤原俊義

日本臨床外科学会雑誌 78 ( 増刊 ) 370 - 370 2017年10月

バイオイメージングの創薬、診断、治療への展開 EMT-がん微小環境ネットワークの蛍光生細胞イメージングシステム査読

家田偉史, 田澤大, 菊地覚次, 黒田新士, 大原利章, 野間和広, 岸本浩行, 永坂岳司, 西崎正彦, 香川俊輔, 今村健志, 藤原俊義

日本癌学会総会記事 76回 S15 - 7 2017年9月

鉄キレート剤特異的な腫瘍幹細胞性抑制効果の検討査読

桂佑貴, 大原利章, 賀島肇, 佐藤浩明, 加藤卓也, 二宮卓之, 野間和広, 友野靖子, 田澤大, 香川俊輔, 白川靖博, 藤原俊義

日本癌学会総会記事 76回 E - 1014 2017年9月

癌関連線維芽細胞(CAFs)により放出されるIL-6が腫瘍免疫抑制を引き起こす査読

加藤卓也, 野間和広, 賀島肇, 桂佑貴, 佐藤浩明, 二宮卓之, 大原利章, 田澤大, 香川俊輔, 藤原俊義

日本癌学会総会記事 76回 P - 1260 2017年9月

スキルス胃癌に対する蛍光発現腫瘍融解ウイルスと化学療法の併用による新たな診断的治療戦略

石川亘, 菊地覚次, 田澤大, 黒田新士, 野間和広, 岸本浩行, 永坂岳司, 西崎正彦, 浦田泰生, 香川俊輔, 藤原俊義

日本癌学会総会記事 76回 E - 3031 2017年9月

Cancer-associated fibroblasts contribute to tumor immunosuppression by regulating tumor-infiltrating lymphocytes

Takuya Kato, Kazuhiro Noma, Hajime Kashima, Yuki Katsura, Hiroaki Sato, Takayuki Ninomiya, Toshiaki Ohara, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

CANCER RESEARCH 77 2017年7月

Fluorescence-guided spatiotemporal dynamics of epithelial-mesenchymal transition under inflammatory microenvironment during colorectal cancer progression

Takeshi Ieda, Hiroshi Tazawa, Satoru Kikuchi, Shinji Kuroda, Toshiaki Ohara, Kazuhiro Noma, Hiroyuki Kishimoto, Takeshi Nagasaka, Masahiko Nishizaki, Shunsuke Kagawa, Takeshi Imamura, Toshiyoshi Fujiwara

CANCER RESEARCH 77 2017年7月

Tumorigenesis of murine iPS cell is prevented by iron depletion with downregulation of stemness markers

Yuki Katsura, Toshiaki Ohara, Hajime Kashima, Hiroaki Sato, Takuya Kato, Takayuki Ninomiya, Kazuhiro Noma, Yasuko Tomono, Hiroshi Tazawa, Shunsuke Kagawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

CANCER RESEARCH 77 2017年7月

Cancer associated fibroblasts promote tumor metastasis coexisting with cancer cells in blood circulation

Hajime Kashima, Kazuhiro Noma, Hiroaki Sato, Yuki Katsura, Takuya Kato, Toshiaki Ohara, Hiroshi Tazawa, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

CANCER RESEARCH 77 2017年7月

Nonexposure laparoscopic and endoscopic cooperative surgery (closed laparoscopic and endoscopic cooperative surgery) for gastric submucosal tumor.

Satoru Kikuchi, Masahiko Nishizaki, Shinji Kuroda, Shunsuke Tanabe, Kazuhiro Noma, Shunsuke Kagawa, Yasuhiro Shirakawa, Hiroshi Kato, Hiroyuki Okada, Toshiyoshi Fujiwara

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20 ( 3 ) 553 - 557 2017年5月

記述言語：英語出版者・発行元：SPRINGER

Laparoscopic and endoscopic cooperative surgery (LECS) is increasingly applied for gastric submucosal tumors (SMTs) such as gastrointestinal stromal tumors. However, the conventional LECS procedure has the potential risk that gastric contents and even tumor cells could spread into the abdominal cavity because the gastric wall has to be opened during the resection. To avoid this problem, we have developed a modified LECS procedure named "closed LECS." Ten patients underwent closed LECS for the resection of gastric SMTs. Closed LECS consists of the following steps: endoscopic submucosal layer dissection around the tumor, laparoscopic marking of a resection line on the serosal surface along submucosal dissection line, seromuscular suturing with the marked lesion inverted into the inside of the stomach, endoscopic circumferential seromuscular dissection, and peroral retrieval. In three of the initial five cases, the closed LECS procedure was not completed as planned because of the tumor size and endoscopic inappropriate seromuscular dissection. After modification of the procedure, the entire procedure was successful in all five cases. The mean resected tumor diameter was 24.1 +/- 7.6 mm. The mean operation time was 253 +/- 45 min. One patient experienced an intra-abdominal abscess potentially related to delayed perforation as a postoperative complication. The closed LECS procedure for gastric SMTs can theoretically be applied without contamination and tumor cell dissemination into the abdominal cavity.

DOI： 10.1007/s10120-016-0641-1

Nonexposure laparoscopic and endoscopic cooperative surgery (closed laparoscopic and endoscopic cooperative surgery) for gastric submucosal tumor

Satoru Kikuchi, Masahiko Nishizaki, Shinji Kuroda, Shunsuke Tanabe, Kazuhiro Noma, Shunsuke Kagawa, Yasuhiro Shirakawa, Hiroshi Kato, Hiroyuki Okada, Toshiyoshi Fujiwara

GASTRIC CANCER 20 ( 3 ) 553 - 557 2017年5月

記述言語：英語出版者・発行元：SPRINGER

DOI： 10.1007/s10120-016-0641-1

Nonexposure laparoscopic and endoscopic cooperative surgery (closed laparoscopic and endoscopic cooperative surgery) for gastric submucosal tumor

Satoru Kikuchi, Masahiko Nishizaki, Shinji Kuroda, Shunsuke Tanabe, Kazuhiro Noma, Shunsuke Kagawa, Yasuhiro Shirakawa, Hiroshi Kato, Hiroyuki Okada, Toshiyoshi Fujiwara

GASTRIC CANCER 20 ( 3 ) 553 - 557 2017年5月

記述言語：英語出版者・発行元：SPRINGER

DOI： 10.1007/s10120-016-0641-1

Outcome of Radiation Monotherapy for High-risk Patients with Stage I Esophageal Cancer

Yasuhiro Shirakawa, Kazuhiro Noma, Naoaki Maeda, Shunsuke Tanabe, Shinji Kuroda, Shunsuke Kagawa, Kuniaki Katsui, Norihisa Katayama, Susumu Kanazawa, Toshiyoshi Fujiwara

ACTA MEDICA OKAYAMA 71 ( 2 ) 127 - 133 2017年4月

記述言語：英語出版者・発行元：OKAYAMA UNIV MED SCHOOL

Currently, chemoradiation is the most widely used nonsurgical treatment for esophageal cancer. However, some patients, particularly the very elderly or those with severe vital organ dysfunction, face difficulty with the chemotherapy component. We therefore examined the outcome of radiation therapy (RT) alone for patients with esophageal cancer at our facility. Between January 2005 and December 2014, 84 patients underwent RT at our hospital, and 78 of these patients received concomitant chemotherapy. The remaining 6 patients underwent RT alone; these patients were considered to be high-risk and to have no lymph node metastasis (stage I). Five of them received irradiation up to a curative dose: 4 showed a complete response (CR) and 1 showed a partial response (PR). Of the patients exhibiting CR, 3 are currently living recurrence-free, whereas 1 patient underwent endoscopic submucosal dissection (ESD) as salvage therapy for local recurrence, with no subsequent recurrence. High-risk stage I esophageal cancer patients can be treated radically with RT alone under certain conditions. In the future, to broaden the indications for RT monotherapy to include some degree of advanced cancers, a novel concurrent therapy should be identified.